Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

NCT06272656 is registered in ClinicalTrials.gov with Hebei Medical University Third Hospital as lead sponsor.

NCT NCT06272656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06272656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Lead sponsor
Hebei Medical University Third Hospital
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2024
Completion date
June 30, 2025
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma